747P - Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Prostate Cancer
Presenter Noel Clarke
Citation Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372
Authors N.W. Clarke1, M. De Santis2, A.J. Costello3, Y. Chang4, T. Pickles5, A.C. Pompeo6, S. Bazarbashi7, G.P. Haas8, M.R. Cooperberg9
  • 1Urology, The Christie Hospital, M204BX - Manchester/GB
  • 2Cancer Research Centre, University of Warwick, Coventry/GB
  • 3Oncology, The Royal Melbourne Hospital, Melbourne/AU
  • 4Division Of General Urology, Taipei Veterans General Hospital, Taipei/TW
  • 5Developmental Radiotherapy And Radiotherapeutics, University of British Columbia, Vancouver/CA
  • 6Urology, FM-ABC, Sao Paulo/BR
  • 7Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh/SA
  • 8Astellas Pharma Global Development, Astellas Pharma Inc., Northbrook/US
  • 9Urologic Surgery And Oncology, University of California, San Francisco/US



ASPIRE-PCa is an observational study that aims to describe the pattern of care for men with late-stage prostate cancer (PC). 1200 patients (pts) from the Americas, Europe, Asia, and the Middle East/North Africa are targeted for enrolment. We present updated data from December 2015.


Men with prostate adenocarcinoma enrol at the diagnosis of: biochemical failure after curative-intent therapy with a prostate-specific antigen (PSA) doubling time of ≤1 year; castration-resistant PC (CRPC); or metastatic PC (mPC) at initial presentation. Initial treatment decision and planned follow-up data were collected.


507 pts have enrolled from 72 sites in 21 countries: Americas, n = 53; Europe, n = 172; Asia, n = 271; and the Middle East/North Africa, n = 11. Biochemical failure, n = 90 (18%); CRPC, n = 181 (36%); mPC, n = 235 (46%); and missing, n = 1 (100%, as >1 option/pt). Enzalutamide was less frequently chosen (n = 7; 3%). The most favoured follow-up was PSA testing every 3 months. Updated regional differences will be presented.

New treatment,a n (%) 277 (109%)
Androgen-deprivation therapy 244 (88%)
Chemotherapy, immunotherapy, targeted therapy 46 (17%)
Salvage radiotherapy 11 (4%)
Androgen-deprivation therapy, n (%) 223 (∼100%)
GnRH agonist and anti-androgen 90 (40%)
GnRH agonist alone 67 (30%)
Anti-androgen alone 26 (12%)
2nd-generation androgen-directed therapy 25 (11%)
Treatment missing 7 (3%)
GnRH antagonist alone 4 (2%)
GnRH antagonist and anti-androgen 2 (


The updated results from ASPIRE-PCa indicate that most late-stage PC pts receive ADT as a GnRH agonist/aa combination; disease status drives treatment choice; and the most common follow-up is PSA testing every 3 months. Leuprolide and bicalutamide are the most common initial interventions.

Clinical trial identification

NCT02066961 - First received: February 18, 2014; Last updated: February 4, 2016

Legal entity responsible for the study

Astellas Pharma, Inc.


Astellas Pharma, Inc.


N.W. Clarke: Advisory boards for Astellas, AstraZeneca, Bayer, Ferring, Janssen, Ipsen, Sanofi Aventis and Pfizer.

M. De Santis, S. Bazarbashi: The author discloses that they are a member of the ASPIRE steering comitee and have received a research grant from Astellas Pharma Inc.

T. Pickles: The author discloses that they have a substantive relationship with Sanofi Aventis and Oncurra.

G.P. Haas: The author discloses that they are the senior medical director at Astellas Pharma Inc.

M.R. Cooperberg: Employee of Astellas Pharma, Inc.

All other authors have declared no conflicts of interest.